Quanterix rises as Q4 results beat expectations
** Shares of diagnostic co Quanterix Corp QTRX.O rise 6.9%
to $12.95
** Co posts Q4 adj. loss of 50 cents per share vs Refinitiv
IBES est. for a loss of 47 cents per share
** Reports a 3.5% rise in revenue to $35.25 bln from a year
earlier, also beating analysts' expectation of $25.78 mln
** All 4 brokerages covering the stock rate it "hold";
median PT $14 - Refinitiv data
** In 2022, QTRX fell 67.3% in value
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Quanterix
See all newsBrief: Alzpath And Quanterix Expand Strategic Licensing Agreement To Advance Next Generation Alzheimer's Disease Biomarker Research
Quanterix Corporation reports results for the quarter ended June 30 - Earnings Summary
Quanterix Q2 revenue rises 34% but cuts 2026 outlook
Quanterix Corporation expected to post a loss of 46 cents a share - Earnings Preview
Quanterix Corp expected to post a loss of 46 cents a share - Earnings Preview